Parvovirus B19 transmission by a high-purity factor VIII concentrate

Transfusion

Volumn 45, Issue 6, 2005, Pages 1003-1010

  Wu, Chuan Ging ^b   Mason, Bobby ^b   Jong, Julia ^b   Erdman, Dean ^b   McKernan, Laurel ^b   Oakley, Meredith ^b   Soucie, Mike ^b   Evatt, Bruce ^b   Yu, Mei Ying W ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; DETERGENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; SOLVENT; VIRUS ANTIBODY; VIRUS DNA;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; GENE SEQUENCE; HEMOPHILIA A; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PARVOVIRUS; PLASMA; SEQUENCE ANALYSIS; SERUM; VIRAL CONTAMINATION; VIRUS GENE; VIRUS INFECTION; VIRUS TRANSMISSION;

CLONING, MOLECULAR; DETERGENTS; DNA, VIRAL; FACTOR VIII; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PHYLOGENY; PLASMA; SEQUENCE ANALYSIS, DNA; SEROLOGIC TESTS; SOLVENTS;

EID: 20444390562     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.04387.x     Document Type: Article

References (36)

1. Young NS, Brown KE. Mechanisms of disease: parvovirus B19. N Engl J Med 2004;350:586-97.
2. Anderson MJ, Tsou C, Parker RA, et al. Detection of antibodies and antigen of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986;24:522-6.
3. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988;25:151-3.
4. Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998;75:97-102.
5. Aubin JT, Defer C, Vidaud M, Maniez MM, Flan B. Large-scale screening for human parvovirus B19 DNA by PCR. application to the quality control of plasma for fractionation. Vox Sang 2000;78:7-12.
6. Weimer T, Streichert S, Watson C, Gröner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001;41:1500-4.
7. Siegl G, Cassinotti P. Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998;26:89-94.
8. Luban NLC. Human parvoviruses: implications for transfusion medicine. Transfusion 1994;34:821-7.
9. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996;93:714-9.
10. Eis-Hübinger AM, Sasowski U, Brackmann HH. Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost 1999;81:476-7.
11. Schmidt I, Blümel J, Seitz H, Willkommen H, Löwer J. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang, 2001;81:228-35.
12. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999;13:194-204.
13. Azzi A, Ciappi S, Zakvrzewska K, et al. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992;39:228-30.
14. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996;93:457-9.
15. Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization. Transfusion 1997;37:517-22.
16. Matsui H, Sugimoto M, Tsuji S, et al. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate [case report]. J Pediatr Hematol Oncol 1999;21:74-6.
17. Blümel J, Schmidt I, Effenberger W, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002;42:1473-81.
18. Schosser R, Keller-Stanislawski B, Nübling M, Löwer J. Causality assessment of suspected virus transmission by human plasma products. Transfusion 2001;41:1020-9.
19. Saldanha J, Lelie N, Yu MW, Heath A: B19 Collaborative Study Group. Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 2002;82:24-31.
20. Blood safety monitoring among persons with bleeding disorders-United States, May 1998-June 2002. MMWR Morb Mortal Wkly Rep 2003;51:1152-4.
21. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986;58:921-36.
22. Blundell MC, Beard C, Astell CR. In vitro identification of a B19 parvovirus promoter. Virology 1987;157:534-8.
23. Bhattacharyya SP, Tan D, Guo ZP, et al. Presence of human parvovirus B19 DNA in factor VIII concentrates: effects of viral clearance and product purification procedures. Haemophilia 2000;6:353.
24. Blümel J, Schmidt I, Willkommen H, Löwer J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002;42:1011-8.
25. Yunoki M, Tsujikawa M, Urayama T, et al. Heat sensitivity of human parvovirus B19. Vox Sang 2003;84:164-9.
26. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003;9:24-37.
27. Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002;76:9124-34.
28. Dorsch S, Kaufmann B, Schaible U, et al. The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability. J Gen Virol 2001;82:191-9.
29. Blood Products Advisory Committee. Nucleic acid testing of blood donors for human parvovirus B19 [Internet]. Rockville (MD): U.S. Food and Drug Administration; 1999. Available from: http://www.fda.gov/ohrms/dockets/ac/99/ transcript/3548t1.rtf
30. Davenport R, Geohas G, Cohen S, et al. Phase IV study of PLAS+ SD: hepatitis A (HAV) and parvovirus B19 safety results. Blood 2000;96:451a.
31. Koenigbauer U, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000;40:1203-6.
32. Brown KE, Young NS, Alving BM, LH, Barbosa. Parvovirus B19: implications for transfusion medicine, summary of a workshop. Transfusion 2001;41:130-5.
33. Tabor E, Yu MW, Hewlett I, Epstein JS. Summary of a workshop on the implementation of NAT to screen donors of blood and plasma for viruses. Transfusion 2000;40:1273-5.
34. Hewlett IK, Yu MW, Epstein JS. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology. The International Forum. Vox Sang 2002;82:87-111.
35. Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002;42:1230-7.
36. Aberham C, Pendl C, Gross P, Zerlauth G, Gessner M. A quantitative, internally controlled real-time PCR assay for the detection of parvovirus B19 DNA. J Virol Methods 2001;92:183-91.